Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 10/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539480 | 1.00 | CYP1A2 (0.57) | CYP1A2SCN5AMETNQO2PDE3B | |
| SCHEMBL26539034 | 1.00 | CYP1A2 (0.57) | CYP1A2SCN5AMETNQO2PDE3B | |
| SCHEMBL20203897 | 0.92 | CYP1A2 (0.68) | CYP1A2SCN5AMETNQO2PDE3B | |
| SCHEMBL20203740 | 0.92 | CYP1A2 (0.68) | CYP1A2SCN5AMETNQO2PDE3B | |
| SCHEMBL23522703 | 0.92 | CYP1A2 (0.68) | CYP1A2SCN5AMETNQO2PDE3B | |
| SCHEMBL26539661 | 0.83 | CYP1A2 (0.43) | CYP1A2SCN5AMETPDE3BPDE3A | |
| SCHEMBL26539659 | 0.83 | CYP1A2 (0.43) | CYP1A2SCN5AMETPDE3BPDE3A | |
| SCHEMBL26539658 | 0.83 | CYP1A2 (0.43) | CYP1A2SCN5AMETPDE3BPDE3A | |
| SCHEMBL26539815 | 0.82 | CYP1A2 (0.84) | CYP1A2SCN5AMETALDH1A1 | |
| SCHEMBL26308610 | 0.82 | CYP1A2 (0.38) | CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885MET 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.